Hip Bursitis Injection Treatment: The GTPS vs. Iliopsoas Protocol That Determines Which Injection You Actually Need

Introduction: Why ‘Hip Bursitis Injection’ Is Not a One-Size-Fits-All Answer

A patient receives a diagnosis of “hip bursitis,” gets a cortisone shot, and returns three months later still experiencing significant pain. This scenario occurs with frustrating regularity, and understanding why requires looking beyond the oversimplified label of “hip bursitis.”

The term “hip bursitis” functions as an umbrella covering at least two anatomically and pathologically distinct conditions: Greater Trochanteric Pain Syndrome (GTPS) and iliopsoas bursitis. These conditions affect different structures, present with different symptoms, and respond to different treatment protocols.

A significant paradigm shift has occurred in orthopedic medicine. What physicians once called “trochanteric bursitis” is now understood to be GTPS, where tendinopathy—not bursal inflammation—is frequently the primary driver of pain. This distinction matters clinically because the wrong injection type, or an injection without the correct diagnosis, can mean months of ineffective treatment.

This article walks through the diagnostic and anatomical differences between GTPS and iliopsoas bursitis, explains which injection protocols apply to each, and honestly evaluates the current evidence—including the landmark 2025 HIPPO Trial—so patients can have more informed conversations with their providers about hip bursitis injection treatment.

Understanding the Two Main Types of Hip Bursitis: Anatomy First

The hip contains over 20 bursae, but two are clinically significant for bursitis: the trochanteric bursa on the outer hip and the iliopsoas bursa on the inner/groin side. Accurate identification of which bursa—or which structure—is involved represents the essential first step before any injection is considered. The American Academy of Orthopaedic Surgeons recognizes both as common conditions, though trochanteric bursitis (now GTPS) occurs more frequently.

Greater Trochanteric Pain Syndrome (GTPS): The Outer Hip Condition

GTPS describes pain over the greater trochanter on the outer hip, historically called trochanteric bursitis. Modern understanding has evolved considerably: histological studies demonstrate that the pain most often originates from gluteal medius and minimus tendinopathy, not isolated bursal inflammation—though coexisting bursitis sometimes occurs.

The Merck Manual Professional Edition (2026) notes that isolated trochanteric bursitis is now believed to occur rarely, with lateral hip pain more often representing gluteal tendinopathy.

GTPS affects an estimated 10–25% of the general population, with an incidence rate as high as 1.8 patients per 1,000 annually. The condition predominantly affects middle-aged women and is associated with comorbidities including low back pain, obesity, iliotibial band tenderness, and diabetes mellitus—which research published in the Journal of Clinical Medicine (2023) identified as a risk factor.

Typical symptoms include lateral hip pain that worsens with lying on the affected side, climbing stairs, or prolonged walking. The terminology shift from “trochanteric bursitis” to “GTPS” matters clinically because it changes both the injection target and the expected treatment response.

Iliopsoas Bursitis: The Inner Hip/Groin Condition

Iliopsoas bursitis involves inflammation of the iliopsoas bursa, located between the iliopsoas tendon and the hip joint on the anterior/groin side. Typical symptoms include deep groin or anterior hip pain, sometimes accompanied by a snapping sensation (coxa saltans), and pain with hip flexion.

Post-total hip arthroplasty (THA) patients face elevated risk for this condition, as iliopsoas bursitis is a recognized complication following hip replacement surgery. The femoral nerve runs in close proximity to this bursa, making precise injection technique especially critical.

The distinction from GTPS is clear: different location, different anatomy, different injection approach, and a different evidence base.

Why Getting the Diagnosis Right Changes Everything About the Injection

The diagnostic process involves physical examination findings—point tenderness over the greater trochanter versus groin pain with resisted hip flexion—as well as provocative tests and imaging. MRI can identify gluteal tendinopathy, partial tears, and bursitis, while ultrasound visualizes bursal fluid and tendon pathology in real time.

Injection can also serve as a diagnostic tool—a concept most patient-facing content overlooks. A local anesthetic injection that relieves pain confirms the bursa or tendon sheath as the pain source, providing important information for treatment planning.

The clinical implication is significant: if GTPS is primarily tendinopathy-driven, injecting the bursa alone may not address the root pathology. Research published in the American Journal of Roentgenology examining 183 injections found that sonographic findings (tendinopathy, bursitis, enthesopathy) do not reliably predict response to corticosteroid injection, reinforcing that diagnosis must guide treatment selection—not imaging findings alone.

A provider who treats all lateral hip pain as “trochanteric bursitis” requiring a cortisone shot is working from an outdated framework.

The GTPS Injection Protocol: What the Evidence Actually Supports

Injection therapy is typically a second-line treatment after conservative measures—rest, NSAIDs, physical therapy, and activity modification—have failed. According to the 2022 ISHA consensus, 60–90% of GTPS patients respond positively to conservative management, meaning injection is not always the first step.

Corticosteroid Injection for GTPS: Short-Term Relief With Long-Term Limitations

The standard corticosteroid injection (CSI) protocol typically involves triamcinolone acetonide or methylprednisolone acetate (40–80 mg) combined with a local anesthetic such as lidocaine.

Key efficacy data comes from a landmark randomized controlled trial by Brinks et al. (Annals of Family Medicine, 2011), which found 55% recovery at 3 months versus 34% with usual care (NNT=5)—but no significant difference at 12 months. Broader data shows pain relief for approximately 50–80% of patients in the weeks following injection, though about 30% may require additional injections within a year.

The long-term limitation must be stated explicitly: CSI does not appear to alter the long-term disease course. It functions as a pain management tool, not a cure.

Side effects include temporary pain flare, flushing, insomnia, and elevated blood glucose; steroid flare lasting 1–3 days; skin dimpling and fat atrophy at the injection site; and—with repeated injections—tendon weakening and increased rupture risk. Patients should wait at least 3 months between injections. Diabetic patients require blood glucose monitoring post-injection, and diabetes itself is a risk factor for developing GTPS.

PRP for GTPS: What the 2025 HIPPO Trial Changed

Platelet-rich plasma (PRP) has gained significant patient interest as a regenerative alternative for GTPS. The rationale appears sound: PRP delivers concentrated growth factors to promote tendon healing, which is theoretically well-suited to GTPS given its tendinopathy-dominant pathology.

However, the landmark 2025 HIPPO Trial (Atchia et al., JBJS, March 2025) fundamentally changed the evidence landscape. This double-blinded randomized controlled trial of 79 patients found that leukocyte-rich PRP (LR-PRP) did not produce superior clinical outcomes compared to placebo (saline) for refractory GTPS at any follow-up point up to 12 months. The researchers concluded that routine PRP use is not recommended for GTPS based on this high-quality evidence.

A 2022 network meta-analysis (13 RCTs, 1,034 patients) found PRP and shockwave therapy had the best short-term (1–3 month) pain scores versus controls, but no therapy significantly outperformed no-treatment at 6–12 months. A June 2025 narrative review in Cureus concluded that PRP requires further research before inclusion in standard protocols for GTPS. Patients considering PRP injections for GTPS should discuss the HIPPO Trial findings with their provider.

Dry Needling: A Viable Alternative to Cortisone for GTPS

Dry needling (DN) represents a lesser-known but evidence-supported option for GTPS. A randomized clinical trial (Brennan et al., JOSPT 2017) demonstrated that dry needling was non-inferior to cortisone injection for GTPS, with fewer adverse side effects. The mechanism targets the tendinopathic tissue directly, aligning with the tendinopathy-dominant understanding of GTPS. This option warrants consideration for patients who want to avoid corticosteroid side effects or who have contraindications to steroid injection.

The Role of Exercise and Physical Therapy: What Injections Cannot Replace

Evidence indicates that structured exercise may be superior to injection for long-term functional outcomes in GTPS. The 2022 network meta-analysis found structured exercise had the highest probability of being best for functional outcomes, and the June 2025 Cureus review noted that targeted physiotherapy offers superior long-term outcomes compared to shockwave therapy and corticosteroid injections.

The clinical implication is clear: injection therapy—whether CSI or PRP—is best understood as a pain-reduction bridge that allows patients to engage in rehabilitation, not a standalone cure. Any injection should be paired with a structured physical therapy program targeting gluteal strengthening and load management.

The Iliopsoas Bursitis Injection Protocol: A Different Anatomy, A Different Approach

Iliopsoas bursitis has a distinct injection protocol from GTPS, with a separate evidence base. Ultrasound guidance is especially critical because the femoral nerve runs in close proximity to the iliopsoas bursa, making blind or landmark-based injection potentially dangerous.

The standard injection involves ultrasound-guided corticosteroid injection (US-CSI) using a local anesthetic and corticosteroid, delivered precisely into the iliopsoas bursa under real-time imaging.

Evidence for Ultrasound-Guided Corticosteroid Injection in Iliopsoas Bursitis

A 2025 systematic review found NRS pain scores improved from a mean of 7.33 pre-injection to 2.47 post-injection across 3 studies—a clinically significant reduction. A retrospective study (Journal of Arthroplasty, 2023) of 52 post-THA patients found 78.6% had resolution of groin pain at last follow-up with US-CSI. For post-THA patients, iliopsoas bursitis is a recognized complication; selective steroid and anesthetic injections should be considered before surgical release or component revision.

The evidence for corticosteroid injection in iliopsoas bursitis is more straightforwardly supportive than for GTPS because the pathology is primarily bursal inflammation, not tendinopathy.

When Injection Alone Is Not Enough for Iliopsoas Bursitis

In cases where injection provides temporary relief but symptoms recur, the underlying cause—such as hip impingement or post-THA component positioning—must be addressed. For post-THA patients, persistent iliopsoas bursitis despite injection may indicate a need for component revision or surgical iliopsoas tendon release. In these cases, injection serves to buy time and confirm the diagnosis.

Surgery (endoscopic bursectomy) is rarely needed and reserved for cases refractory to all conservative and injection treatments.

Imaging Guidance for Hip Bursitis Injections: Ultrasound vs. Fluoroscopy vs. Landmark-Based

Three approaches exist for imaging guidance: landmark-based (blind), fluoroscopy-guided (X-ray), and ultrasound-guided. Ultrasound guidance improves needle placement accuracy compared to landmark-based methods. However, a multicenter RCT (Cohen et al., BMJ 2009) found no significant difference in clinical pain outcomes between fluoroscopy-guided and blind injections—suggesting imaging improves accuracy without necessarily improving outcomes for all patients.

Ultrasound is increasingly preferred over fluoroscopy due to real-time soft tissue visualization, no ionizing radiation, lower cost, and the ability to avoid neurovascular structures. Ultrasound is particularly critical for iliopsoas injections given femoral nerve proximity, and for patients with obesity or unusual anatomy where landmark-based approaches are less reliable.

Unicorn Bioscience utilizes precision-guided injection using advanced imaging (ultrasound and X-ray) as a standard part of the injection protocol, aligning with best-practice recommendations.

Comparing the Two Protocols Side by Side: GTPS vs. Iliopsoas Bursitis

GTPS:

• Location: Outer hip/lateral pain
• Pathology: Tendinopathy-dominant
• CSI: Short-term benefit; no long-term disease modification
• PRP: Not recommended by current best evidence (HIPPO Trial 2025)
• Alternative: Dry needling is a viable option
• Long-term: Exercise superior for functional outcomes
• Imaging: Preferred but not always essential

Iliopsoas Bursitis:

• Location: Groin/anterior hip pain
• Pathology: Bursal inflammation-dominant
• US-CSI: Strong evidence for pain reduction (NRS 7.33 to 2.47)
• Special population: Post-THA patients at elevated risk
• Imaging: Ultrasound guidance essential given femoral nerve proximity

A misdiagnosis—treating iliopsoas bursitis with a trochanteric bursa injection, or vice versa—will likely result in treatment failure.

Conclusion: Matching the Diagnosis to the Right Injection Protocol

“Hip bursitis injection treatment” is not a single intervention—it is a category of treatments that must be matched to a specific diagnosis, anatomy, and patient profile. Even the best-supported injection—corticosteroid for GTPS—does not alter long-term disease course; exercise and rehabilitation remain essential. For both conditions, accurate needle placement matters, and ultrasound-guided injection is increasingly the standard of care.

Armed with this information, patients can ask better questions: “Is this GTPS or iliopsoas bursitis?” “What imaging will guide the injection?” “What is the evidence for this injection type for my specific diagnosis?” “What rehabilitation plan will accompany the injection?”

Ready to Find Out Which Hip Injection Protocol Is Right?

For patients seeking a personalized, imaging-guided assessment of their hip pain and a treatment protocol matched to their specific diagnosis, Unicorn Bioscience offers the expertise and multi-modal approach to deliver exactly that.

Key differentiators include advanced ultrasound and X-ray imaging guidance for all injections, personalized treatment planning based on individual patient factors (inflammation levels, age, injury type, medications, and health goals), and access to multiple treatment modalities beyond corticosteroids—including PRP, BMAC, and hyaluronic acid—for appropriate candidates.

Both virtual and in-person consultations are available, with same-day treatment for qualified candidates.

Locations: Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, Boca Raton, and Manhattan.

Schedule a consultation: Call (737) 347-0446 or visit unicornbioscience.com.

The team at Unicorn Bioscience—with training from institutions including Johns Hopkins—evaluates each patient’s specific hip anatomy and diagnosis before recommending any injection, ensuring treatment matches the condition rather than applying a one-size-fits-all approach.